Avantor (AVTR)
(Delayed Data from NYSE)
$24.41 USD
+0.31 (1.29%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $24.40 -0.01 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.41 USD
+0.31 (1.29%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $24.40 -0.01 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
Zacks News
Elevance (ELV) Q1 Earnings Beat on Rate Hikes, Guidance Raised
by Zacks Equity Research
Elevance Health (ELV) has a leftover capacity of around $3.6 billion under its share buyback authorization.
BLCO vs. AVTR: Which Stock Is the Better Value Option?
by Zacks Equity Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
Why Is Viatris (VTRS) Down 3.5% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
BLCO or AVTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
Pediatrix Medical Group, Inc. (MD) Up 11% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pediatrix Medical Group, Inc. (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BLCO or AVTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
New Strong Sell Stocks for February 20th
by Zacks Equity Research
HAFC, AVTR and WHD have been added to the Zacks Rank #5 (Strong Sell) List on February 20, 2024.
Avantor (AVTR) Q4 Earnings & Revenues Top Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft fourth-quarter performance.
Compared to Estimates, Avantor, Inc. (AVTR) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Avantor, Inc. (AVTR) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Curious about Avantor, Inc. (AVTR) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Avantor, Inc. (AVTR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
ELV vs. AVTR: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. AVTR: Which Stock Is the Better Value Option?
Viatris (VTRS) Up 5.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avantor's (AVTR) New Offerings to Aid Cell and Gene Therapy Suite
by Zacks Equity Research
Avantor's (AVTR) latest offerings are likely to provide its customers with products, materials and services that would aid in accelerating therapeutics.
Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft third-quarter performance.
Compared to Estimates, Avantor, Inc. (AVTR) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Avantor, Inc. (AVTR) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Avantor, Inc. (AVTR) Q3 Earnings Meet Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 0% and 1.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity's (RVTY) New Launch to Widen Access to Editing Technology
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to improve access to new-generation editing technology and bridge both preclinical and clinical discoveries with the same technology platform.
Alignment Healthcare (ALHC) Soars 5.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alignment Healthcare (ALHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Avantor's (AVTR) Tie-Up to Address Temperature-Specific Logistics
by Zacks Equity Research
Avantor's (AVTR) partnership is likely to meet the growing need among biopharma and life science companies for end-to-end solutions.
New Strong Sell Stocks for September 11th
by Zacks Equity Research
AVTR, TECH and CPRI have been added to the Zacks Rank #5 (Strong Sell) List on September 11, 2023.
Charles River (CRL) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Revvity (RVTY) Down 4.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.